Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Accumulated Expenses (2021 - 2026)

Nuvectis Pharma has reported Accumulated Expenses over the past 6 years, most recently at $6.4 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $6.4 million for Q1 2026, up 645.32% from a year ago — trailing twelve months through Mar 2026 was $6.4 million (up 645.32% YoY), and the annual figure for FY2025 was $6.9 million, up 24.32%.
  • Accumulated Expenses reached $6.4 million in Q1 2026 per NVCT's latest filing, down from $6.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $6.9 million in Q4 2025 and bottomed at $75000.0 in Q3 2025.
  • Median Accumulated Expenses over the past 5 years was $486000.0 (2024), compared with a mean of $1.8 million.
  • The largest annual shift saw Accumulated Expenses surged 1576.76% in 2022 before it crashed 82.57% in 2023.
  • Over 5 years, Accumulated Expenses stood at $2.4 million in 2022, then plummeted by 82.57% to $415000.0 in 2023, then soared by 1238.8% to $5.6 million in 2024, then grew by 24.32% to $6.9 million in 2025, then decreased by 6.66% to $6.4 million in 2026.
  • Business Quant data shows Accumulated Expenses for NVCT at $6.4 million in Q1 2026, $6.9 million in Q4 2025, and $75000.0 in Q3 2025.